HOWL - Werewolf Therapeutics, Inc.

Insider Sale by Evnin Luke (Dir)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

4 days ago, Evnin Luke, serving as Dir at Werewolf Therapeutics, Inc. (HOWL), sold 205,911 shares at $0.75 per share, for a total transaction value of $154,525.00. Following this transaction, Evnin Luke now holds 1,953,949 shares of HOWL.

This sale represents a 10.00% decrease in Evnin Luke's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, April 27, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, April 29, 2026, 2 days after the trade was made.

Werewolf Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Evnin Luke

Evnin Luke

Dir

Luke Evnin, Ph.D., age 61, is a prominent biotech venture capitalist and Chair of the Board at Werewolf Therapeutics, Inc. (HOWL), a position he has held since August 2019 after serving as President and interim CEO from December 2017 to August 2019[[1]](https://fintool.com/app/research/companies/HOWL/people/luke-evnin)[[2]](https://theorg.com/org/werewolf-therapeutics/org-chart/luke-evnin)[[5]](https://werewolftx.com/our-team/). He co-founded Werewolf in 2017 and remains an independent director, chairing the Nominating & Corporate Governance Committee and serving on the Compensation Committee[[1]](https://fintool.com/app/research/companies/HOWL/people/luke-evnin). Evnin owns approximately 13.4 million shares of HOWL stock[[7]](https://www.gurufocus.com/insider/5238/luke-evnin). Evnin co-founded MPM Capital in 1997, where he serves as Managing Director, leading investments in numerous life sciences companies including co-founding seven MPM portfolio firms such as Harpoon Therapeutics, Maverick Therapeutics (acquired by Takeda), and Potenza Therapeutics (acquired by Astellas)[[1]](https://fintool.com/app/research/companies/HOWL/people/luke-evnin)[[2]](https://theorg.com/org/werewolf-therapeutics/org-chart/luke-evnin)[[3]](https://mpmbioimpact.com/team/luke-evnin-ph-d/)[[4]](https://www.umoja-biopharma.com/team/luke-evnin-ph-d/). With over 30 years in venture capital, including prior roles at Accel Partners, he has served on boards of public and private companies like Oncorus, Syndax Pharmaceuticals, and Pacira Pharmaceuticals, and led Turmeric Acquisition Corp. as CEO from 2020 to 2023[[1]](https://fintool.com/app/research/companies/HOWL/people/luke-evnin)[[2]](https://theorg.com/org/werewolf-therapeutics/org-chart/luke-evnin). He holds an A.B. in Molecular Biology from Princeton University and a Ph.D. in Biochemistry from UCSF[[1]](https://fintool.com/app/research/companies/HOWL/people/luke-evnin)[[2]](https://theorg.com/org/werewolf-therapeutics/org-chart/luke-evnin)[[4]](https://www.umoja-biopharma.com/team/luke-evnin-ph-d/). Evnin also chairs the Scleroderma Research Foundation[[1]](https://fintool.com/app/research/companies/HOWL/people/luke-evnin)[[2]](https://theorg.com/org/werewolf-therapeutics/org-chart/luke-evnin).

View full insider profile →

Trade Price

$0.75

Quantity

205,911

Total Value

$154,525.00

Shares Owned

1,953,949

Trade Date

Monday, April 27, 2026

4 days ago

SEC Filing Date

Wednesday, April 29, 2026

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

Discussion

Sign in to join the discussion.
Loading comments…
View news mentioning HOWL

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/6054754

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime